Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Updates on Cardiovascular Drug Therapy
share announcement

Updates on Cardiovascular Drug Therapy

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: closed (25 May 2023) | Viewed by 4603

Special Issue Editor

Prof. Dr. Miguel Castelo-Branco Sousa

E-Mail Website
Guest Editor
Centro Academico Clinico das Beiras, Centro Hospitalar Universitário Cova da Beira, Faculdade de Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal
Interests: cardiovascular medicine; telemonitoring; hypertension; chronic diseases; medical education, emer-gency medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

There has been a significant development in the treatment of cardiovascular diseases, including the pharmacological approach in recent years, this evolution has been in the development of medicines with already known active principles but with the intention of greater efficacy and safety, but also in the identification of new approaches. The objective has been to control diseases by reducing morbidity and death and improving quality of life. With the introduction of new concepts, ACE inhibitors and thrombolytics in the 1980s, and more recently, gliflozins, it is becoming possible to improve survival and reduce complications. On the prevention side, the introduction of statins has also brought a new era. However, survival, although improved is still menaced, and problems persist, some of them growing obesity among others

This Special Issue of the Journal of Clinical Medicine will cover but is not limited to the following important aspects：

  • New approaches to cardiovascular disease drug therapy
  • New targets fo cardiovascular drug therapy
  • Increasing survival
  • Reducing disease impact

Prof. Dr. Miguel Castelo-Branco Sousa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular drug therapy
  • new approaches
  • reducing events
  • increasing survival
  • reducing structural impact
  • reducing clinical impact
  • coronary heart disease
  • peripheral arterial disease
  • ischemic hearth disease
  • renal artery stenosis
  • aortic aneurysm

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 912 KiB  
Article
The Safety and Efficacy of Ultrasound-Accelerated Catheter-Directed Thrombolysis in Patients with Intermediate–High-Risk Pulmonary Embolism: Bo-NE-Experience
by Hani Al-Terki, Andreas Mügge, Michael Gotzmann, Vedat Tiyerili, Friederike Klein, Marcus Franz, Sven Möbius-Winkler and Abdelrahman Elhakim
J. Clin. Med. 2023, 12(10), 3459; https://doi.org/10.3390/jcm12103459 - 14 May 2023
Cited by 1 | Viewed by 1100
Abstract
Ultrasound-accelerated thrombolysis (USAT) is an advanced interventional therapy for patients with intermediate–high-risk pulmonary embolism (PE) who deteriorated on anticoagulation or for high-risk patients for whom systemic thrombolysis is contraindicated. The aim of this study is to investigate the safety and efficacy of this [...] Read more.
Ultrasound-accelerated thrombolysis (USAT) is an advanced interventional therapy for patients with intermediate–high-risk pulmonary embolism (PE) who deteriorated on anticoagulation or for high-risk patients for whom systemic thrombolysis is contraindicated. The aim of this study is to investigate the safety and efficacy of this therapy with a focus on the improvement of vital signs and laboratory parameters. Seventy-nine patients with intermediate–high-risk PE were treated with USAT from August 2020 to November 2022. The therapy significantly decreased the mean RV/LV ratio from 1.2 ± 0.22 to 0.9 ± 0.2 (p < 0.001) as well as the mean PAPs from 48.6 ± 11 to 30.1 ± 9.0 mmHg (p < 0.001). The respiratory and heart rate decreased significantly (p < 0.001). Serum creatinine decreased significantly from 1.0 ± 0.35 to 0.9 ± 0.3 (p < 0.001). There were 12 access-associated complications, which could be treated conservatively. One patient had haemothorax after the therapy and had to be operated on. USAT is an effective therapy for patients with intermediate–high-risk PE, with favourable hemodynamic, clinical, and laboratory outcomes. Full article
(This article belongs to the Special Issue Updates on Cardiovascular Drug Therapy)
►▼ Show Figures

Figure 1

14 pages, 2443 KiB  
Article
A Comparison among Nonvitamin K Antagonist Oral Anticoagulants in Asian Patients with Venous Thromboembolism: A Multi-Institutional Study
by Ming-Lung Tsai, Cheng-Hung Lee, Ming-Jer Hsieh, Shao-Wei Chen, Shang-Hung Chang, Chi-Nan Tseng, Pao-Hsien Chu, I-Chang Hsieh, Po-Chuan Ko, Yu-Tung Huang and Dong-Yi Chen
J. Clin. Med. 2022, 11(23), 7159; https://doi.org/10.3390/jcm11237159 - 01 Dec 2022
Viewed by 1913
Abstract
The comparison of clinical effectiveness and safety across different nonvitamin K antagonist direct oral anticoagulants (DOACs) in Asian patients with venous thromboembolism (VTE) remains unclear. Therefore, we assessed the real-world benefits of different DOACs in these patients. A cohort of 1480 patients with [...] Read more.
The comparison of clinical effectiveness and safety across different nonvitamin K antagonist direct oral anticoagulants (DOACs) in Asian patients with venous thromboembolism (VTE) remains unclear. Therefore, we assessed the real-world benefits of different DOACs in these patients. A cohort of 1480 patients with VTE were identified from the Chang Gung Research Database between 1 January 2012, and 31 December 2019. The composite outcomes of recurrent VTE and major bleeding were evaluated for four DOACs. The composite outcomes of recurrent VTE and major bleeding occurred in 9.06%, 9.80%, 8.61%, and 10.86% of the apixaban, dabigatran, edoxaban, and rivaroxaban groups, respectively, within 12 months of treatment initiation. The risk of the composite outcomes was similar in the rivaroxaban group and the apixaban, dabigatran, and edoxaban groups, with a subdistribution hazard ratio (SHR) of 0.80 (95% CI, 0.49–1.29), 0.81 (95% CI, 0.34–1.95), and 0.76 (95% CI, 0.42–1.39), respectively. No significant differences in the rates of recurrent VTE or major bleeding were observed between the rivaroxaban and other DOAC groups at the 12-month follow-up. According to real-world practice in Asian patients with VTE, the DOAC type was not associated with the differences in the risk of recurrent VTE or major bleeding within 12 months of treatment initiation. Full article
(This article belongs to the Special Issue Updates on Cardiovascular Drug Therapy)
►▼ Show Figures

Figure 1

12 pages, 1424 KiB  
Article
A Multi-Center, Prospective Observational Study to Investigate the Safety, Compliance, and Efficacy of Omethyl QTlet Soft Capsule
by You-Jeong Ki, Sang-Jin Han, Tae-Joon Cha, Jae Hyuk Lee, Eui Kyo Seo, Jae Won Yang, Won Min Hwang, Dong Kyu Jin, Joo-Hyun Park, Han Young Ryu, Chang Gyu Park, Jun Hong Lee, Si Wan Choi, Eun Jeong Cho and Weon Kim
J. Clin. Med. 2022, 11(23), 6949; https://doi.org/10.3390/jcm11236949 - 25 Nov 2022
Viewed by 1202
Abstract
Omega-3 fatty acids have been shown to be effective in lowering triglyceride (TG) levels; however, tolerability issues arise due to the large size of the pills. The purpose of this study was to examine the safety, compliance, and efficacy of Omethyl QTlet soft [...] Read more.
Omega-3 fatty acids have been shown to be effective in lowering triglyceride (TG) levels; however, tolerability issues arise due to the large size of the pills. The purpose of this study was to examine the safety, compliance, and efficacy of Omethyl QTlet soft capsules (OQCs). This multi-center, prospective, observational study evaluated the safety, compliance, and efficacy of OQCs. Patients with hypertriglyceridemia with a history of omega-3 fatty acid intake were enrolled in this study and were prescribed OQCs (2 g–4 g/day) for eight weeks. All adverse events (AEs), adverse drug reactions (ADRs), and serious adverse events (SAEs) were recorded for safety evaluation. Adherence to treatment was assessed using questionnaires, and efficacy was assessed by changes in lipid and lipoprotein levels after eight weeks from baseline. The convenience of taking medication was analyzed for 580 patients, and the efficacy test was performed for 563 patients. The AE and ADR rates were 8.2% and 5.7%, respectively. There were only two SAEs. Of the patients, 55.8% responded that the OQC improved medication convenience, and mean changes in TG, total cholesterol, LDL-C, and non-HDL-C from baseline to eight weeks were −37.88 mg/dL, −11.56 mg/dL, −5.55 mg/dL, and −10.87 mg/dL, respectively (p-values < 0.001). In patients who had previously taken omega-3 fatty acids, OQCs showed safety and efficacy in lowering TG, and it was confirmed that compliance with medicine also improved compared to omega-3 fatty acids. Full article
(This article belongs to the Special Issue Updates on Cardiovascular Drug Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop